Apellis Pharmaceuticals (NASDAQ:APLS) posted a quarterly loss of $(0.73) per share in Q4, which was 5.8% lower than the analyst consensus estimate of $(0.69). This marks a 51.33% increase in losses compared to the same period last year. The company’s quarterly sales totaled $146.38 million, exceeding the analyst consensus estimate of $143.59 million by 1.94%. This represents a significant 545.89% increase in sales compared to the same period last year.
For the current fiscal year, analysts project Apellis Pharmaceuticals to report a loss per share of $4.485, a stark contrast to the $6.150 profit from the previous year. The company disclosed net losses of $88.5 million and $528.6 million for the fourth quarter and full year 2023, respectively. Throughout 2023, Apellis generated revenues of $397 million, largely driven by robust sales of SYFOVRE® and EMPAVELI®.
Date: February 27, 2024
Apellis Pharmaceuticals Inc. (APLS) Sees Significant Price Increase on February 27, 2024
On February 27, 2024, Apellis Pharmaceuticals Inc. (APLS) experienced a significant price increase, with shares rising by $3.26 or 4.76% since the market last closed. This surge in price momentum is notable, as APLS is currently trading near the top of its 52-week range and above its 200-day simple moving average.
As of the last market close, APLS shares were priced at $71.73. However, in pre-market trading, the stock has since dropped by $3.61.
Despite the drop in pre-market trading, the overall price performance of APLS on February 27, 2024, indicates a strong upward trend. The 4.76% increase in share price demonstrates investor confidence in the company and its potential for future growth.
Investors and analysts will be closely monitoring APLS stock throughout the trading day to see how the price performance evolves. The drop in pre-market trading may present a buying opportunity for some investors, while others may choose to wait and see how the stock performs throughout the day.
Overall, the price momentum of APLS on February 27, 2024, suggests that the company is experiencing positive market sentiment and may continue to see upward movement in the near future. Investors should continue to monitor the stock closely for any further developments.
APLS Stock Performance Analysis: Revenue Up, Net Income Down – February 27, 2024 Financial Report
On February 27, 2024, APLS stock had an interesting performance based on the financial data provided by CNN Money. The company reported a total revenue of $75.42 million over the past year, which increased by 13.31% compared to the previous year. In the most recent quarter, the total revenue was $110.40 million, showing a significant increase of 16.25% compared to the previous quarter.
However, the net income for APLS was not as positive. The company reported a net income of -$652.17 million over the past year, which actually increased by 12.62% compared to the previous year. In the most recent quarter, the net income was -$140.24 million, showing a decrease of 14.91% compared to the previous quarter.
Earnings per share (EPS) for APLS also showed a mixed performance. The EPS over the past year was -$6.15, which increased by 30.48% compared to the previous year. However, in the most recent quarter, the EPS was -$1.17, showing a decrease of 13.98% compared to the previous quarter.
Overall, the stock performance of APLS on February 27, 2024, was influenced by the mixed financial results. Investors may want to closely monitor the company’s financial performance in the coming quarters to assess its long-term growth potential.
